Bluebird Bio reported $36.69M in Selling and Administration Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Agios Pharmaceuticals AGIO:US $ 28.26M 3.25M
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
Amgen AMGN:US $ 1.33B 99M
Applied Genetic Technologies AGTC:US $ 4.32M 494K
Arrowhead Research ARWR:US $ 32.74M 1.12M
Avrobio Inc AVRO:US 8.9M 1.27M
Biogen BIIB:US $ 572.6M 62.3M
Biomarin Pharmaceutical BMRN:US $ 196.83M 2.22M
Bluebird Bio BLUE:US $ 36.69M 588K
Gilead Sciences GILD:US $ 1.36B 274M
Immunogen IMGN:US $ 23.79M 7.14M
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
IONIS PHARMACEUT IONS:US $ 33.8M 325K
Mirati Therapeutics MRTX:US $ 54.23M 277K
Moderna Inc MRNA:US 211M 57M
Nektar Therapeutics NKTR:US $ 21.44M 5.9M
Novartis NOVN:VX 3.59B 91M
Pfizer PFE:US $ 3.2B 506M
Ptc Therapeutics PTCT:US $ 79.89M 6.62M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M
Sangamo Biosciences SGMO:US $ 15.09M 185K
Sarepta Therapeutics SRPT:US $ 154.32M 82.48M
Seattle Genetics SGEN:US $ 220.26M 46.03M
Ultragenyx Pharmaceutical RARE:US $ 68.14M 825K
Vertex Pharmaceuticals VRTX:US $ 215.3M 100K
YTE INCY:US $ 253.28M 43.69M